Vol 2 (April 25, 2024): AME Clinical Trials Review

ADAURA: redefining the role of target therapy in resectable lung adenocarcinoma

Is osimertinib effective as 2nd line treatment in T790M-negative EGFR mutant NSCLC?

Immunotherapy unleashed: pioneering chemo-free neoadjuvant programmed cell death ligand 1 (PD-L1) inhibition for resectable non-small cell lung cancer (NSCLC)

New treatment options for crizotinib-resistant ALK-positive non-small cell lung cancer patients

Confirmatory surgical exploration of the mediastinum after negative endobronchial ultrasound-guided transbronchial needle aspiration: which method and when to perform it, if needed

Neoadjuvant osimertinib: a promising therapeutic option for locally advanced EGFR-mutant lung adenocarcinoma

Chest tube after lung resection—a small change to a great benefit

How to navigate an increasingly heterogeneous spectrum of resistance mechanisms in oncogene driven non-small cell lung cancer?

Genomic and molecular considerations for sotorasib treatment in KRAS G12C-mutant non-small cell lung cancer

Utilization of pharmacokinetics in the dosing of pembrolizumab in non-small cell lung cancer

Breaking barriers: bridging the gap in lung cancer trials through inclusive representation

Optimizing the role of immunotherapy in the management of resectable non-small cell lung cancer

The ELUCIDATE trial: a step closer to complete resection of lung tumors

NEOSTAR platform trial: neoadjuvant dual immunotherapy plus chemotherapy—more is better?

Combination metronomic chemotherapy and immunotherapy in non-small cell lung cancer remains exploratory: the VinMetAtezo trial

Immunotherapy as first-line treatment in locally advanced/metastatic and previously untreated squamous cell lung cancer: which advances?